Is there an indication for sentinel node biopsy in patients with ductal carcinoma in situ of the breast? A review

European Journal of Cancer

Volumn 43, Issue 6, 2007, Pages 993-1001

  van Deurzen, C H M ^a   Hobbelink, M G G ^a   van Hillegersberg, R ^a   van Diest, P J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Breast cancer; Ductal carcinoma in situ; Sentinel node

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER SIZE; CANCER STAGING; CARCINOMA IN SITU; CELL ISOLATION; EPITHELIUM CELL; HUMAN; INVASIVE CARCINOMA; MASTECTOMY; MULTIPLE CANCER; PRIORITY JOURNAL; SAMPLING ERROR; SENTINEL LYMPH NODE BIOPSY; TUMOR CELL;

BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY;

EID: 33947607328     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.01.010     Document Type: Article

References (111)

1. Mokbel K. Towards optimal management of ductal carcinoma in situ of the breast. Eur J Surg Oncol 29 (2003) 191-197 [review]
2. Mokbel K. Treatment of ductal carcinoma in situ of the breast: review of recent advances and future prospects. Int J Fertil Womens Med 48 (2003) 217-225 [review]
3. Sakorafas G.H., and Farley D.R. Optimal management of ductal carcinoma in situ of the breast. Surg Oncol 12 (2003) 221-240 [review]
4. Baxter N.N., Virnig B.A., Durham S.B., and Tuttle T.M. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96 (2004) 443-448
5. Meijnen P., Peterse J.L., Oldenburg H.S., Woerdeman L.A., and Rutgers E.J. Changing patterns in diagnosis and treatment of ductal carcinoma in situ of the breast. Eur J Surg Oncol 31 (2005) 833-839
6. Collins L.C., and Schnitt S.J. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol 18 (2005) 615-620
7. Vleugel M.M., Bos R., Van der Groep P., et al. Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol 57 (2004) 746-751
8. Ernster V.L., Barclay J., Kerlikowske K., Wilkie H., and Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160 (2000) 953-958
9. Silverstein M.J., Rosser R.J., Gierson E.D., et al. Axillary lymph node dissection for intraductal breast carcinoma-is it indicated. Cancer 59 (1987) 1819-1824
10. Silverstein M.J., Gierson E.D., Colburn W.J., Rosser R.J., Waisman J.R., and Gamagami P. Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstet 172 (1991) 211-214
11. Yiangou C., Shousha S., and Sinnett H.D. Primary tumour characteristics and axillary lymph node status in breast cancer. Br J Cancer 80 (1999) 1974-1978
12. Solin L.J., Kurtz J., Fourquet A., et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 14 (1996) 754-763
13. Silverstein M.J., Skinner K.A., and Lomis T.J. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 25 (2001) 767-772
14. Zelis J.J., Sickle-Santanello B.J., Liang W.C., and Nims T.A. Do not contemplate invasive surgery for ductal carcinoma in situ. Am J Surg 184 (2002) 348-349
15. van Diest P.J. Histopathological workup of sentinel lymph nodes: how much is enough. J Clin Pathol 52 (1999) 871-873
16. Lyman G.H., Giuliano A.E., Somerfield M.R., et al. American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23 (2005) 7703-7720
17. Giuliano A.E., Kirgan D.M., Guenther J.M., and Morton D.L. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220 (1994) 391-398 [discussion 398-401]
18. Veronesi U., Paganelli G., Galimberti V., et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349 (1997) 1864-1867
19. Gipponi M., Bassetti C., Canavese G., et al. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. J Surg Oncol 85 3 (2004) 102-111 [review]
20. van Diest P.J., Torrenga H., Meijer S., and Meijer C. Pathological analysis of sentinel lymph nodes. Sem Surg Oncol 20 (2001) 238-245
21. Torrenga H., Rahusen F.D., Meijer S., Borgstein P.J., and van Diest P.J. Sentinel node investigation in breast cancer: detailed analysis of the yield from step sectioning and immunohistochemistry. J Clin Pathol 54 (2001) 550-552
22. Giuliano A.E., Dale P.S., Turner R.R., Morton D.L., Evans S.W., and Krasne D.L. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222 (1995) 394-399 [discussion 399-401, review]
23. Turner R.R., Ollila D.W., Krasne D.L., and Giuliano A.E. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 226 (1997) 271-276 [discussion 276-8]
24. Liu L.H., Siziopikou K.P., Gabram S., and McClatchey K.D. Evaluation of axillary sentinel lymph node biopsy by immunohistochemistry and multilevel sectioning in patients with breast carcinoma. Arch Pathol Lab Med 124 (2000) 1670-1673
25. Pargaonkar A.S., Beissner R.S., Snyder S., and Speights Jr. V.O. Evaluation of immunohistochemistry and multiple-level sectioning in sentinel lymph nodes from patients with breast cancer. Arch Pathol Lab Med 127 (2003) 701-705
26. Klauber-DeMore N., Tan L.K., Liberman L., et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in situ and ductal carcinoma-in-situ with microinvasion. Ann Surg Oncol 7 (2000) 636-642
27. Kelly T.A., Kim J.A., Patrick R., Grundfest S., and Crowe J.P. Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. Am J Surg 186 (2003) 368-370
28. Farkas E.A., Stolier A.J., Teng S.C., Bolton J.S., and Fuhrman G.M. An argument against routine sentinel node mapping for DCIS. Am Surg 70 (2004) 13-17 [discussion 17-8]
29. Trisal V., Qian D., and Wagman L.D. Axillary recurrence in DCIs: is axillary lymphadenectomy warranted. Am Surg 70 (2004) 876-880
30. Buttarelli M., Houvenaeghel G., Martino M., et al. Interest of sentinel lymph node biopsy for the staging of ductal carcinoma in situ. Ann Chir 129 (2004) 508-512
31. Zavagno G., Carcoforo P., Marconato R., et al. Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer 5 (2005) 28
32. Mittendorf M.E., Arciero C.A., Gutchell V., Hooke J., and Shriver C.D. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg 62 (2005) 253-257
33. Giard S., Chauvet M.P., Houpeau J.L., et al. Sentinel node biopsy without systematic axillary dissection: study about 1000 procedures. Gynecol Obstet Fertil 33 (2005) 213-219
34. Yen T.W., Hunt K.K., Ross M.I., et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 200 (2005) 516-526
35. Schrenk P., Konstantiniuk P., Wolfl S., et al. Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node. Br J Surg 92 (2005) 707-713
36. Wilkie C., White L., Dupont E., Cantor A., and Cox C.E. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg 190 (2005) 563-566
37. Camp R., Feezor R., Kasraeian A., et al. Sentinel lymph node biopsy for ductal carcinoma in situ: an evolving approach at the University of Florida. Breast J 11 (2005) 394-397
38. Veronesi P., Intra M., Vento A.R., et al. Sentinel lymph node biopsy for localised ductal carcinoma in situ. Breast 14 (2005) 520-522
39. Torok K., Peley G., Matrai Z., et al. The role of sentinel lymph node biopsy in breast cancer non-invading-duct. Magy Seb 59 (2006) 173-178
40. Cserni G., Boross G., Maraz R., et al. Sentinel lymph node biopsy for in situ carcinoma of the breast. Experience at the Bacs-Kiskun County Hospital and review of the literature. Magy Seb 59 (2006) 164-172 [review]
41. Katz A., Gage I., Evans S., et al. Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 191 (2006) 761-766
42. Mabry H., Giuliano A.E., and Silverstein M.J. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ. Am J Surg 192 (2006) 455-457
43. Sakr R., Barranger E., Antoine M., Prugnolle H., Darai E., and Uzan S. Ductal carcinoma in situ: value of sentinel lymph node biopsy. J Surg Oncol 94 (2006) 426-430 [review]
44. Leidenius M., Salmenkivi K., von Smitten K., and Heikkila P. Tumour-positive sentinel node findings in patients with ductal carcinoma in situ. J Surg Oncol 94 (2006) 380-384
45. Fraile M., Gubern J.M., Rull M., et al. Is it possible to refine the indication for sentinel node biopsy in high-risk ductal carcinoma in situ. Nucl Med Commun 27 (2006) 785-789
46. Leonard G.D., and Swain S.M. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96 (2004) 906-920 [review]
47. Moore K.H., Thaler H.T., Tan L.K., Borgen P.I., and Cody III H.S. Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact. Cancer 100 (2004) 929-934
48. King T.A., Ganaraj A., Fey J.V., et al. Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy. Cancer 101 (2004) 926-933
49. Jackman R.J., Nowels K.W., Shepard M.J., Finkelstein S.I., and Marzoni F.A. Stereotaxic large-core needle biopsy of 450 nonpalpable breast lesions with surgical correlation in lesions with cancer or atypical hyperplasia. Radiology 193 (1994) 91-95
50. Liberman L., Dershaw D.D., Rosen P.P., et al. Stereotaxic core biopsy of breast carcinoma accuracy at predicting invasion. Radiology 194 (1995) 379-381
51. Acheson M.B., Patton R.G., Howisey R.L., Lane R.F., and Morgan A. Histologic correlation of image-guided core biopsy with excisional biopsy of nonpalpable breast lesions. Arch Surg 132 (1997) 815-821
52. Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions improved accuracy with directional, vacuum-assisted biopsy. Radiology 202 (1997) 843-847
53. Fuhrman G.M., Cederbom G.J., Bolton J.S., et al. Image-guided core-needle breast biopsy is an accurate technique to evaluate patients with nonpalpable imaging abnormalities. Ann Surg 227 (1998) 932-939
54. Won B., Reynolds H.E., Lazaridis C.L., and Jackson V.P. Stereotactic biopsy of ductal carcinoma in situ of the breast using an 11-gauge vacuum assisted device persistent underestimation of disease. AJR 173 (1999) 227-229
55. Burak W.E., Owens K.E., Tighe M.B., et al. Vacuum-assisted stereotactic breast biopsy. Arch Surg 135 (2000) 700-703
56. Darling M.L., Smith D.N., Lester S.C., et al. Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy results of surgical excision. AJR 175 (2000) 1341-1346
57. Lee C.H., Carter D., Philpotts L.E., et al. Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy can invasion be predicted?. Radiology 217 (2000) 466-470
58. Cox C.E., Nguyen K., Gray R.J., et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS. Am Surg 67 (2001) 513-519 [discussion 519-21]
59. Brem R.F., Schoonjans J.M., Sanow L., and Gatewood O.M.B. Reliability of histologic diagnosis of breast cancer with stereotactic vacuum-assisted biopsy. Am Surg 67 (2001) 388-392
60. Jackman R.J., Burbank F., Parker S.H., et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 218 (2001) 497-502
61. King T.A., Farr Jr. G.H., Cederbom G.J., et al. A mass on breast imaging predicts coexisting invasive carcinoma in patients with a core biopsy diagnosis of ductal carcinoma in situ. Am Surg 67 (2001) 907-912
62. Renshaw A.A. Predicting invasion in the excision specimen from breast core needle biopsy specimens with only ductal carcinoma in situ. Arch Pathol Lab Med 126 (2002) 39-41
63. Verkooijen H.M. Core Biopsy After Radiological Localisation (COBRA) Study Group. Diagnostic accuracy of stereotactic large-core needle biopsy for nonpalpable breast disease: results of a multicenter prospective study with 95% surgical confirmation. Int J Cancer 99 (2002) 853-859
64. Pandelidis S., Heilman D., Jones D., Stough K., Trapeni J., and Suliman Y. Accuracy of 11-gauge vacuum-assisted core biopsy of mammographic breast lesions. Ann Surg Oncol 10 (2003) 43-47
65. Crowe J.P., Patrick R.J., Rybicki L.A., et al. Does ultrasound core breast biopsy predict histologic finding on excisional biopsy. Am J Surg 186 (2003) 397-399
66. Hoorntje L.E., Schipper M.E., Peeters P.H., Bellot F., Storm R.K., and Borel Rinkes I.H. The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy. Ann Surg Oncol 10 (2003) 748-753
67. Goyal A., Douglas-Jones A., Monypenny I., Sweetland H., Stevens G., and Mansel R.E. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ? analysis of 587 cases. Breast Cancer Res Treat 98 (2006) 311-314
68. Borgstein P.J., Pijpers R., Comans E.F., van Diest P.J., Boom R.P., and Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 186 (1998) 275-283
69. Cox C.E., Pendas S., Cox J.M., et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 227 (1998) 645-651
70. Krag D., Weaver D., Ashikaga T., et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 339 (1998) 941-946
71. Feldman S.M., Krag D.N., McNally R.K., Moor B.B., Weaver D.L., and Klein P. Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. J Am Coll Surg 188 (1999) 248-254
72. McMasters K.M., Wong S.L., Martin II R.C., et al. University of Louisville Breast Cancer Study Group. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 233 (2001) 676-687
73. Martin R.C., Derossis A.M., Fey J., et al. Intradermal isotope injection is superior to intramammary in sentinel node biopsy for breast cancer. Surgery 130 (2001) 432-438
74. Barnwell J.M., Arredondo M.A., Kollmorgen D., et al. Sentinel node biopsy in breast cancer. Ann Surg Oncol 5 (1998) 126-130
75. Miner T.J., Shriver C.D., Jaques D.P., Maniscalco-Theberge M.E., and Krag D.N. Sentinel lymph node biopsy for breast cancer: the role of previous biopsy on patient eligibility. Am Surg 65 (1999) 493-498 [discussion 498-9]
76. Haigh P.I., Hansen N.M., Qi K., and Giuliano A.E. Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann Surg Oncol 7 (2000) 21-27
77. Wong S.L., Edwards M.J., Chao C., et al. University of Louisville Breast Cancer Study Group. The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann Surg Oncol 9 (2002) 272-277
78. Luini A., Galimberti V., Gatti G., et al. The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology. Breast Cancer Res Treat 89 (2005) 159-163
79. Chagpar A.B., Scoggins C.R., Sahoo S., et al. Biopsy type does not influence sentinel lymph node status. Am J Surg 190 (2005) 551-556
80. Vijayakumar V., Boerner P.S., Jani A.B., and Vijayakumar S. A critical review of variables affecting the accuracy and false-negative rate of sentinel node biopsy procedures in early breast cancer. Nucl Med Commun 26 (2005) 395-405
81. Chagpar A.B., Martin R.C., Scoggins C.R., et al. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery 138 (2005) 56-63
82. De Cicco C., Trifiro G., Intra M., et al. Optimised nuclear medicine method for tumour marking and sentinel node detection in occult primary breast lesions. Eur J Nucl Med Mol Imag 31 (2004) 349-354
83. Patel A., Pain S.J., Britton P., et al. Radioguided occult lesion localisation (ROLL) and sentinel node biopsy for impalpable invasive breast cancer. Eur J Surg Oncol 30 (2004) 918-923
84. Schneidereit N.P., Davis N., Mackinnon M., Speers C.H., Truong P.T., and Olivotto I.A. T1a breast carcinoma and the role of axillary dissection. Arch Surg 138 (2003) 832-837
85. Kader H.A., Jackson J., Mates D., Andersen S., Hayes M., and Olivotto I.A. Tubular carcinoma of the breast: a population-based study of nodal metastases at presentation and of patterns of relapse. Breast J 7 (2001) 8-13
86. Schrenk P., Rieger R., Shamiyeh A., and Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 88 (2000) 608-614
87. Swenson K.K., Nissen M.J., Ceronsky C., Swenson L., Lee M.W., and Tuttle T.M. Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol 9 (2002) 745-753
88. Golshan M., Martin W.J., and Dowlatshahi K. Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection. Am Surg 69 (2003) 209-211 [discussion 212]
89. Schijven M.P., Vingerhoets A.J., Rutten H.J., et al. Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol 29 (2003) 341-350
90. Peintinger F., Reitsamer R., Stranzl H., and Ralph G. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer 89 (2003) 648-652
91. Purushotham A.D., Upponi S., Klevesath M.B., et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 23 (2005) 4312-4321
92. Rietman J.S., Dijkstra P.U., Geertzen J.H., et al. Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for Stage I or II breast carcinoma. Cancer 98 (2003) 690-696
93. Rietman J.S., Geertzen J.H., Hoekstra H.J., et al. Long term treatment related upper limb morbidity and quality of life after sentinel lymph node biopsy for stage I or II breast cancer. Eur J Surg Oncol 32 (2006) 148-152
94. Sener S.F., Winchester D.J., Martz C.H., et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer 92 (2001) 748-752
95. Ronka R., von Smitten K., Tasmuth T., and Leidenius M. One-year morbidity after sentinel node biopsy and breast surgery. Breast 14 (2005) 28-36
96. Haid A., Kuehn T., Konstantiniuk P., et al. Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol 28 (2002) 705-710
97. Albo D., Wayne J.D., Hunt K.K., et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg 182 (2001) 393-398
98. Kuerer H.M., Wayne J.D., and Ross M.I. Anaphylaxis during breast cancer lymphatic mapping. Surgery 129 (2001) 119-120
99. Ronka R., Smitten K., Sintonen H., et al. The impact of sentinel node biopsy and axillary staging strategy on hospital costs. Ann Oncol 15 (2004) 88-94
100. Gipponi M., Bassetti C., Canavese G., et al. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. J Surg Oncol 85 (2004) 102-111 [review]
101. Bolster M.J., Bult P., Schapers R.F., et al. Differences in sentinel lymph node pathology protocols lead to differences in surgical strategy in breast cancer patients. Ann Surg Oncol 13 (2006) 1466-1473
102. Gemignani M.L., Cody III H.S., Fey J.V., Tran K.N., Venkatraman E., and Borgen P.I. Impact of sentinel lymph node mapping on relative charges in patients with early-stage breast cancer. Ann Surg Oncol 7 (2000) 575-580
103. Perrier L., Nessah K., Morelle M., Mignotte H., Carrere M.O., and Bremond A. Cost comparison of two surgical strategies in the treatment of breast cancer: sentinel lymph node biopsy versus axillary lymph node dissection. Int J Technol Assess Health Care 20 (2004) 449-454
104. Dowlatshahi K., Fan M., Snider H.C., and Habib F.A. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 80 (1997) 1188-1197 [review]
105. Reed W., Bohler P.J., Sandstad B., and Nesland J.M. Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up. Breast J 10 (2004) 174-180
106. Cummings M.C., Walsh M.D., Hohn B.G., Bennett I.C., Wright R.G., and McGuckin M.A. Occult axillary lymph node metastases in breast cancer do matter: results of 10-year survival analysis. Am J Surg Pathol 26 (2002) 1286-1295
107. Cote R.J., Peterson H.F., Chaiwun B., et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 354 (1999) 896-900
108. Tamhane R., Dahlstrom J.E., McCallum D.D., and Buckingham J.M. The clinical significance of cytokeratin-positive cells in lymph nodes at the time of mastectomy from patients with ductal carcinoma-in-situ. Ann Surg Oncol 9 (2002) 999-1003
109. Lara J.F., Young S.M., Velilla R.E., Santoro E.J., and Templeton S.F. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 98 (2003) 2105-2113
110. El-Tamer M., Chun J., Gill M., et al. Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ. Ann Surg Oncol 12 (2005) 254-259
111. Broekhuizen L.N., Wijsman J.H., Peterse J.L., and Rutgers E.J. The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. Eur J Surg Oncol 32 (2006) 502-506